N/A N=22 Pilot Study of Multi-wavelength Laser for Tattoo Removal
Tattoo Removal
Primary: Degree of Tattoo Clearing at 6 Weeks Post-final Treatment as Assessed by the Investigator — 2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=56 Wetness Sensing System
System Validation
Primary: Sensor Detection — 96.15 percentage of passes
N/A N=10 Study of a Novel Laser for Skin Rejuvenation
Rejuvenation
Primary: Degree of Improvement as Assessed by the Investigator (Physician's Global Assessment of Improvement). — 1.7 score on a scale
Phase 1 N=12 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants
N/A N=100 Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)
Anterior Wall Acute Myocardial Infarction
Primary: Rate of Net Adverse Clinical Events (NACE) — 7; 0; 1; 1 Participants
N/A N=27 Multi-Center, Clinical Evaluation of the Cutera Secret RF Device
Skin Quality
Primary: Overall Aesthetic Improvement — 1.63; 2 score on a scale
Phase 3 N=320 Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
Jet Lag Type Insomnia
Primary: Total Sleep Time in the First Two Thirds of the Night — 156.1; 216.4 Minutes — p=<.0001
Phase 2 N=6 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Bone Marrow Failure Syndrome · Thalassemia · Sickle Cell Disease
Primary: Assessment of Minimum Effective Dose (MED) of Thiotepa — 5 mg/kg
N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score
Phase 4 N=90 LIBERATE - LIposomal Bupivacaine vERsus Adjuncts in Total shouldErs
Post-operative Pain · Total Shoulder Arthroplasty · Osteoarthritis of the Shoulder
Primary: Total Opioid Consumption — 71.25; 90.30 MME — p=0.127
Phase 2 N=41 A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)
Muscular Dystrophy, Duchenne
Primary: Change From Baseline at Week 12 in Quantity of Delandistrogene Moxeparvovec Dystrophin Protein Expression as Measured by Western Blot Adjusted by Muscle Content — 4.23…
Phase 2 N=100 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Non-small Cell Lung Carcinoma · Urothelial Carcinoma · Gastrointestinal Carcinoma, Non-colon
Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants
N/A N=76 The Role of Different Prefrontal Areas in Visual Metacognition
Healthy
Primary: Average Confidence Difference With the 0 ms Condition — 0.14; 0.14; 0.14; 0.15 score on a scale (1-4) — p=<.001
Phase 2 N=37 A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Mesothelioma · Uveal Melanoma · Renal Cell Carcinoma
Primary: Objective Response Rate (ORR) — 5.6; 0 percentage of subjects
N/A N=337 SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Acute and Chronic Safety by Evaluating Incidence of Major Adverse Events — 204; 130; 2; 1 Participants